Physician profile
Christopher Russo
NPI 1235456385
$1,734.75
in general payments reported to CMS, 2019-2025
15 companies · $356 in 2025
The $356 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $254 · 2020: $51.07 · 2021: $71.80 · 2022: $216 · 2023: $445 · 2024: $340 · 2025: $356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,141.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $607.04 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $422.64 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $224.44 | 2019-2024 | Camzyos, Eliquis |
| Bridgebio Pharma, INC. | $109.99 | 2025 | Attruby |
| Medtronic, INC. | $97.47 | 2023 | Corevalve Evolut R |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.01 | 2023 | Jardiance |
| Amgen INC. | $38.95 | 2020-2021 | |
| Astrazeneca Pharmaceuticals Lp | $37.77 | 2019-2020 | |
| Lexicon Pharmaceuticals, INC. | $27.61 | 2024 | |
| Cardiva Medical, INC. | $26.47 | 2022 | |
| Novo Nordisk INC | $21.91 | 2024 | Wegovy |
| Lundbeck LLC | $19.93 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.93 | 2025 | |
| Kiniksa Pharmaceuticals, Ltd. | $19.67 | 2021 | |
| Merck Sharp & Dohme LLC | $16.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Russo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.